Tirzepatide is a dual incretin receptor agonist targeting GIP and GLP-1 receptors. This 30mg preparation supports sustained or multi-phase research investigating dual incretin pharmacology, with receptor engagement characterized through cAMP accumulation, β-arrestin recruitment, and metabolic gene expression assays in published studies.
Compound Profile
- Class: Dual incretin receptor agonist (GIPR / GLP-1R)
- Form: Lyophilized peptide, sealed Type I borosilicate vial
- Documented assays: cAMP accumulation, β-arrestin recruitment, metabolic gene expression
- Net content: 30 mg / vial
Quality & Documentation
- Purity: ≥99% verified by reverse-phase HPLC
- Identity: Confirmed by mass spectrometry
- Certificate of Analysis: Batch-specific, lot-traceable, available on request
- Manufacturing: Full analytical characterization per production batch
- Storage: Refrigerate at 36–46°F lyophilized; ~60 day stability reconstituted
Research Use
For qualified research use only. Not intended for administration to any living organism, including human or veterinary subjects.
